



DEINOVE will hold its Annual General
Meeting
on May 20, 2019 in Paris

[Download the legal
documents](#)

[Contact the Investor
Relations team](#)

Grabels, May 3, 2019

Dear Sir or Madam,

The Annual General Meeting of DEINOVE shareholders, which will take place on Monday, May 20, 2019 in Paris, will be an opportunity to review the progress made in 2018:

- The acquisition of the DNV3837 program has profoundly changed your company's profile. This drug candidate in clinical development is intended for the treatment of severe gastrointestinal infections, a disease for which there are few effective options. We are actively preparing for the start of a Phase II clinical trial, scheduled for mid-2019, to demonstrate the full therapeutic potential of DNV3837.
- Our AGIR program to explore the antibiotic potential of rare bacteria has also progressed, which materialized through the implementation of an automated discovery platform and the signing of several research collaborations with Naicons, bioMérieux, and in 2019 the Institut Pasteur.
- We also kept our commitments to the development of natural active ingredients, with the launch of our first proprietary product, PHYT-N-RESIST®, a unique anti-aging active ingredient from our carotenoid research. We now have worldwide distribution agreements with two key partners, Univar and Solvay, which continue to actively prospect for rapid revenue generation. Many potential clients are currently evaluating the asset. The development of the second carotenoid is progressing and will be launched this year. Other developments, owned or in partnership, are underway.
- Finally, TVM Capital, a German fund with a European reach, has become a new long-term shareholder of the Company, which strengthens our capital structure.

The General Meeting is also a privileged opportunity for dialogue with shareholders. We sincerely hope that you will take the time to make your voice heard, at the meeting or at a distance. You will find all the legal documentation on our website and our Investor Relations team is at your disposal for any further information.

Sincerely yours,

Handwritten signature of Charles WOLER in blue ink.

Charles WOLER
Chairman of the Board

Handwritten signature of Emmanuel PETIOT in blue ink.

Emmanuel PETIOT
CEO